TABLE 1.

Patient demographics and clinical characteristics of carfilzomib users and non‐users

Characteristics	Total	Carfilzomib use				p‐value
		Yes	%	No	%
Year of diagnosis
2001–2012	4459	537	12.0	3922	88.0	0.0001
2013	1088	121	11.1	967	88.9
2014	856	92	10.7	764	89.3
2015	927	65	7.0	862	93.0
Age groups
66–69	1813	286	15.8	1527	84.2	<0.0001
70–74	2015	291	14.4	1724	85.6
75–79	1627	146	9.0	1481	91.0
80+	1875	92	4.9	1783	95.1
Sex
Male	3846	429	11.2	3417	88.8	0.9185
Female	3484	386	11.1	3098	88.9
Race/ethnicity
Non‐Hispanic white	5332	640	12.0	4692	88.0	<0.0001
Non‐Hispanic black	1076	98	9.1	978	90.9
Other	400	29	7.3	371	92.8
Hispanic	522	48	9.2	474	90.8
Myeloma
New	5621	355	6.3	5266	93.7	<0.0001
Relapsed	1709	460	26.9	1249	73.1
Previous transplant
No	6483	606	9.3	5877	90.7	<0.0001
Yes	847	209	24.7	638	75.3
Charleston comorbidity index
0	4788	613	12.8	4175	87.2	<0.0001
1	1293	129	10.0	1164	90.0
2	631	41	6.5	590	93.5
3+	618	32	5.2	586	94.8
Body mass index
Other	6775	693	10.2	6082	89.8	<0.0001
Overweight	60	15	25.0	45	75.0
Obesity	495	107	21.6	388	78.4
Nicotine/tobacco use
Never	6565	557	8.5	6008	91.5	<0.0001
Current/former	765	258	33.7	507	66.3
Pre‐existing diabetes
No	4311	465	10.8	3846	89.2	0.2795
Yes	3019	350	11.6	2669	88.4
Pre‐existing hypertension
No	6682	584	8.7	6098	91.3	<0.0001
Yes	648	231	35.6	417	64.4
Pre‐existing cardiovascular conditions
No	3452	302	8.7	3150	91.3	<0.0001
Yes	3878	513	13.2	3365	86.8
Previous anthracycline use
No	7177	755	10.5	6422	89.5	<0.0001
Yes	153	60	39.2	93	60.8